Voyager Therapeutics
NEWS
Alfred Sandrock Jr., the former head of research and development at Biogen, has taken a position on the board of directors of Cambridge, Mass.-based Voyager Therapeutics.
Voyager Therapeutics entered a deal with Pfizer that allows Pfizer to exercise options to license novel capsids created by Voyager’s RNA-driven TRACER screening technology.
Voyager’s primary focus will be on developing gene therapies for Huntington’s disease, Amyotrophic Lateral Sclerosis (ALS), and pre-clinical research in spinal muscular atrophy and diseases linked to GBA1 mutations.
Shares of Voyager Therapeutics fell in aftermarket trading after its CEO and CMO announced plans to depart the company following clinical setbacks with a Parkinson’s disease program.
The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here’s a look at a few of the highlights.
The two companies first partnered in 2019 to develop a gene therapy treatment for Parkinson’s disease, and other neurodegenerative disorders.
In October, the FDA placed a clinical hold on the company’s Huntington’s disease gene therapy before that asset could make its way into the clinic.
Here’s a look at recent clinical trial pauses around the biopharma industry.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
JOBS
IN THE PRESS